Answers are grounded in this paper and cite their sources.
The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome.
No takes yet. Share an insight, caveat, or question.
Enlimomab Acute Stroke Trial Investigators (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: